Radiologix reports mixed results for 2Q
Imaging services provider Radiologix reported a net loss of $2.1 million, or 10¢ per diluted share, compared with net income of $276,000, or 2¢ per diluted share for the same period last year. Income from continuing operations excluding charges and a
Imaging services provider Radiologix reported a net loss of $2.1 million, or 10¢ per diluted share, compared with net income of $276,000, or 2¢ per diluted share for the same period last year. Income from continuing operations excluding charges and a gain on sale of operations rose, however, to $1 million, or 5¢ per diluted share, compared with $898,000, or 4¢ per diluted share in 2Q 2003. Earnings before interest, taxes, depreciation, and amortization (EBITDA) were $12.5 million for 2Q 2004, compared with $12.6 million for 2Q 2003. Adjusted EBITDA as a percentage of service fee revenue was 18.4% for the 2Q 2004, compared with 20.3% for 2Q 2003.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
